Glucose Metabolism Disorders Clinical Trial
Official title:
The "Metabolically-obese Normal-weight" Phenotype in Two Asian Ethnic Groups and Its Reversal by Calorie Restriction
The prevalence of overweight and obesity in Singapore is approximately half of that in the
United States, yet the incidence of type 2 diabetes is similar, and is expected to double in
the near future. This indicates that metabolic dysfunction, particularly insulin resistance,
is widely prevalent even among individuals who are considered normal-weight or lean by
conventional measures, i.e. body mass index (BMI) and percent body fat. These individuals are
often referred to as "metabolically-obese normal-weight" (MONW), and have increased risk for
cardiometabolic disease despite their normal BMI and total body fat values. The prevalence of
the MONW phenotype varies across populations and differs markedly among different
ethnicities. However, our understanding of the complex interactions between ethnicity, body
composition, and metabolic dysfunction and its reversal remains rudimentary. Previous
attempts to characterize the MONW phenotype are confounded by the small but significant
differences in BMI or percent body fat between groups (even if all subjects were lean, within
the "normal" range), with MONW subjects being always "fatter" than the corresponding control
subjects. There are no published studies that prospectively recruited groups of metabolically
healthy and unhealthy lean individuals matched on BMI and percent body fat. Furthermore,
although weight loss improves body composition and many of the cardiometabolic abnormalities
in most obese patients, little is known about the possible therapeutic effects of calorie
restriction in MONW subjects.
Accordingly, a better understanding of the MONW phenotype and the evaluation of therapeutic
approaches for its reversal will have important implications for public health. By
facilitating earlier identification of these subjects, who are more likely to go undiagnosed
and thus less likely to be treated before clinically overt cardiometabolic disease develops,
results from this study will allow for earlier and effective intervention.
By the year 2050, it is estimated that more than half of the Singapore population will be
overweight or obese, defined as having a body mass index (BMI, calculated as the weight in
kilograms divided by the square of height in meters) equal to or greater than 25 kg/m2 (Phan
et al. 2014). This is likely responsible, at least in part, for the concomitant increase in
obesity-related co-morbid conditions, particularly type 2 diabetes (Phan et al. 2014; Ni
Mhurchu et al. 2006). The relationship between BMI and the risk for type 2 diabetes in
populations from the Asia-Pacific region is linear within a wide range of BMI values (from
~21 kg/m2 to ~34 kg/m2), so that for every 2 kg/m2 increase in BMI (which corresponds to ~6
kg for a normal-weight person of average stature), the risk for developing type 2 diabetes
rises by ~27 % (Ni Mhurchu et al. 2006). In Singapore, the prevalence of type 2 diabetes is
expected to double from 7.3 % in 1990 to ~15 % in 2050, predominantly as a result of the
fattening of the population, with the burden being greater for those of Indian descent than
those of Chinese descent (Phan et al. 2014). This is expected to reduce productivity, inflate
healthcare costs, and increase mortality among Singaporeans (Phan et al. 2014; Ma et al.
2003).
The prevalence of type 2 diabetes in Singapore is similar to that in the United States, even
though the prevalence of overweight and obesity (BMI ≥25 kg/m2) in Singapore is approximately
half that in the US (Yoon et al. 2006). This observation corroborates findings from many
studies showing that markers of metabolic dysfunction (e.g. hyperglycemia, hyperinsulinemia,
insulin resistance, dyslipidemia, and hypertension) are highly prevalent among Singaporean
adults even at normal BMI values, i.e. even among people who are considered "normal-weight"
or "lean" by conventional measures (Deurenberg-Yap et al. 1999; Deurenberg-Yap, Chew, et al.
2001). The existence of people who have normal body weight but also have metabolic
dysfunction, and therefore greater risk for developing cardiometabolic disease, was
recognized several decades ago (Ruderman et al. 1998; Ruderman, Schneider, and Berchtold
1981). At the extreme of this paradigm, even among members of the Calorie Restriction Society
who undergo self-imposed calorie restriction for years based on the belief that this will
help them ensure a long and healthy life, there are many individuals (~40 %) with impaired
glucose tolerance, despite very low BMI and total body fat (Fontana, Klein, and Holloszy
2010). These individuals are often referred to as "metabolically-obese normal-weight" (MONW)
or "metabolically-abnormal lean" or "metabolically-unhealthy lean" subjects. The prevalence
of this phenotype ranges from 5 % to 45 % depending on the BMI and the metabolic criteria
used for its definition, as well as the characteristics of the population (i.e. age, sex, and
ethnicity) (Conus, Rabasa-Lhoret, and Peronnet 2007; Teixeira et al. 2015). Similar
variability has been observed across Asia (Lee et al. 2011; Luo et al. 2015; Yoo et al. 2014;
Jung et al. 2015; Indulekha et al. 2015). For example, among the Chinese, ~8 % of the
population as a whole, or ~13 % of those who are considered lean by virtue of body fat
percent (i.e. ≤25 % for men and ≤35 % for women), are metabolically unhealthy, defined as
having three or more metabolic abnormalities characteristic of the metabolic syndrome (Luo et
al. 2015). Among Indians, on the other hand, 15-25 % of the population (or 20-40 % of those
who are considered lean by virtue of BMI, i.e. <25 kg/m2) satisfies the criteria for
metabolic syndrome (Indulekha et al. 2015; Geetha et al. 2011). The MONW phenotype in Asians
is associated with 3-fold greater risk for carotid atherosclerosis (i.e. cardiovascular
disease) (Yoo et al. 2014) and 4.5-8.5-fold greater risk for developing type 2 diabetes (Luo
et al. 2015). In fact, MONW subjects have increased risk for cardiometabolic disease (Luo et
al. 2015; Yoo et al. 2014) and greater all-cause mortality (Choi et al. 2013) not only
compared to metabolically-healthy lean subjects, but also compared to metabolically-healthy
obese subjects. This underscores the importance of metabolic dysfunction independent of
excess body weight and total adiposity.
The mechanisms responsible for the development of metabolic abnormalities in lean people are
not entirely clear. The MONW phenotype can manifest early in life, e.g. during childhood
(Guerrero-Romero et al. 2013), which corroborates the existence of genetic predisposition for
metabolic dysfunction in the face of low BMI values (Yaghootkar et al. 2014). Previous
studies have identified a number of factors associated with the MONW phenotype, including
increased intra-abdominal (visceral) adipose tissue, increased liver and muscle fat content,
increased fat cell size, adipose tissue inflammation, altered inflammatory and adipokine
profiles, reduced skeletal muscle mass, lack of physical activity, and low cardio-respiratory
fitness (Badoud et al. 2015; Dvorak et al. 1999; Ruderman et al. 1998; Conus, Rabasa-Lhoret,
and Peronnet 2007; De Lorenzo et al. 2007; Karelis et al. 2004; Kim et al. 2013; Lee 2009;
Oliveros et al. 2014; Teixeira et al. 2015; Di Renzo et al. 2006; Conus et al. 2004;
Indulekha et al. 2015; Luo et al. 2015; Fontana, Klein, and Holloszy 2010). All of these
factors have been directly or indirectly associated with insulin resistance (defined by a
variety of methods), which is by far the commonest metabolic correlate of the MONW phenotype
across all ethnicities, age groups, and sexes (Conus, Rabasa-Lhoret, and Peronnet 2007;
Oliveros et al. 2014; Karelis et al. 2004; Ruderman et al. 1998). In fact, the greater
prevalence of the MONW phenotype in Indians (Indulekha et al. 2015; Geetha et al. 2011) than
in the Chinese (Luo et al. 2015) mirrors results obtained recently by our team, showing that
among lean Singaporean men (BMI <25 kg/m2 or body fat ≤20 %), those of Indian descent have
significantly lower insulin sensitivity, evaluated as the insulin-mediated glucose disposal
rate during a hyperinsulinemic-euglycemic clamp procedure, compared to those of Chinese
descent (Khoo et al. 2014). Similar results have been reported by other investigators in
smaller groups of subjects (Liew et al. 2003) or when using simpler indices of insulin
sensitivity (Khoo et al. 2011; Tai et al. 2000). Therefore, an insulin resistant glucose
metabolism, broadly defined by subnormal responses to physiological insulin concentrations
(Kahn 1978), is the hallmark of the MONW phenotype.
Owing to the lack of a consistent definition, there is some variability among studies in the
phenotypic characterization of MONW subjects (Teixeira et al. 2015). This is further
complicated by the small but significant differences in BMI and, more commonly, percent body
fat between groups of metabolically healthy and unhealthy lean subjects, with MONW subjects
being always somewhat "fatter" (even though within the "lean" range) (Ruderman et al. 1998;
Di Renzo et al. 2006; Badoud et al. 2015; Luo et al. 2015; Indulekha et al. 2015; Dvorak et
al. 1999; Conus et al. 2004; De Lorenzo et al. 2007). Likewise, BMI and body fat are
typically greater in relatively insulin-resistant (e.g. Indian) than in relatively
insulin-sensitive (e.g. Chinese) individuals in studies reporting on ethnic differences in
insulin action among lean people (Khoo et al. 2014; Khoo et al. 2011). This in itself could
be responsible for the differences observed in metabolic function. There is considerable
(~2-fold range) variability between individuals in the percent body fat (Gallagher et al.
2000; Gallagher et al. 1996) and the insulin-mediated glucose disposal rate (a direct measure
of whole-body insulin sensitivity) (Bradley, Magkos, and Klein 2012) for the same BMI value
within the normal-weight range (i.e. BMI <25 kg/m2), so that people with the same BMI can
have very different body fat and insulin sensitivity without this necessarily being
associated with the presence or absence of generalized metabolic dysfunction. Even among lean
and metabolically-healthy Asians, total body fat is a major correlate of insulin-mediated
glucose disposal (Rattarasarn et al. 2003). It is thus possible that some of the reported
differences between metabolically healthy and unhealthy lean subjects arise from normal
variability and the differences in body fat between groups, rather than being an inherent
characteristic of the MONW phenotype. In support of this possibility, when metabolically
healthy and unhealthy lean subjects (defined as those having normal and impaired glucose
tolerance, respectively) were retrospectively matched on total body fat, there were no
differences between phenotypes in circulating concentrations of metabolic and inflammatory
markers (i.e. high-density lipoprotein (HDL)-cholesterol, triglycerides, free fatty acids,
C-reactive protein, adiponectin, and leptin) (Fontana, Klein, and Holloszy 2010). There are
no studies that prospectively recruited groups of metabolically healthy and unhealthy lean
individuals matched on BMI and percent body fat. A deeper understanding of the MONW
phenotype, as proposed here, is important to dissect the metabolic abnormalities that are
inherent to the phenotype from those merely associated with differences in total body fat.
This will allow for proper identification and more efficient therapeutic targeting of MONW
individuals, who are at greater risk for cardiometabolic disease.
Little is known about possible interventions for improving metabolic function in MONW
subjects. It is well established that diet-induced weight loss can improve body composition
and many of the cardiometabolic abnormalities in most obese patients (e.g. decreases total
body fat, intra-abdominal adipose tissue, and ectopic fat deposition in liver and muscle;
increases insulin sensitivity; improves blood lipid profile; and reduces blood pressure)
(Dattilo and Kris-Etherton 1992; de Leiva 1998; Goldstein 1992; Kirk et al. 2009; Muscelli et
al. 1997; Pi-Sunyer 1993; Pasanisi et al. 2001; Escalante-Pulido et al. 2003; Mazzali et al.
2006; Klein, Wadden, and Sugerman 2002), so that a moderate 10 % weight loss has become the
cornerstone of obesity treatment (Jensen et al. 2014). However, MONW individuals are by
definition lean, so recommending even moderate amounts of weight loss may not be a feasible
therapeutic target (Miller and Parsonage 1975). It is therefore important to better
understand the metabolic effects of smaller amounts of weight loss. Recently, the principal
investigator conducted a randomized controlled trial to evaluate the effects of mild weight
loss (5 % of initial body weight) on cardiometabolic function in non-Asian subjects with
obesity and insulin resistance and found that even this small amount of weight loss decreases
fat deposition in the liver and the intra-abdominal area, and increases insulin action in
skeletal muscle, liver, and adipose tissue (Magkos et al. 2016). These results demonstrate
that mild weight loss can improve many cardiometabolic abnormalities in
metabolically-unhealthy obese subjects, but whether the same holds true for
metabolically-unhealthy lean subjects is not known. A small, non-randomized, single-arm study
in 7 lean, insulin-resistant offspring of parents with type 2 diabetes reported that modest
~6 % diet-induced weight loss reduced intra-myocellular lipid (i.e. fat within skeletal
muscle fibers) content and increased insulin-mediated glucose disposal rate (both by ~30 %
compared with baseline values), but did not significantly affect intra-abdominal adipose
tissue volume or liver fat content (Petersen et al. 2012). It is thus not known whether mild
diet-induced weight loss produces similar changes in body composition, fat distribution, and
metabolic function in lean versus obese metabolically unhealthy subjects.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05081037 -
Integrated Hyperglycaemia Incentivised Postnatal Surveillance Study (I-HIPS)
|
N/A | |
Recruiting |
NCT05544266 -
Rare and Atypical Diabetes Network
|
||
Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A | |
Active, not recruiting |
NCT05505994 -
The Efficacy and Safety of DWP16001 in Combination With Metformin in T2DM Patients Inadequately Controlled on Metformin
|
Phase 3 | |
Completed |
NCT03623139 -
Effects of Basic Carbohydrate Counting Versus Standard Outpatient Nutritional Education in Type 2 Diabetes
|
N/A | |
Completed |
NCT03623113 -
The Dietary Education Trial in Carbohydrate Counting (DIET-CARB Study in Type 1 Diabetes
|
N/A | |
Completed |
NCT03359629 -
Spectrophon LTD Glucometry Monitor Accuracy
|
||
Recruiting |
NCT03682640 -
Azithromycin Insulin Diet Intervention Trial in Type 1 Diabetes
|
Phase 2 | |
Completed |
NCT02697305 -
Incretin Effects of Branched Chain Amino Acids
|
N/A | |
Completed |
NCT01737164 -
Effect of Age on Glucose and Lipid Metabolism
|
N/A | |
Terminated |
NCT00935766 -
Effect of Fish Oil (Omega-3 Fatty Acids) on Arteries
|
Phase 3 | |
Recruiting |
NCT03613688 -
Effects of Deepure(Pu-erh Tea Extract) on Glycemic Control
|
N/A | |
Completed |
NCT04098549 -
The Effect of Rapid and Slow Glucose Fall on the Subsequent Glucose Production in People With Type 1 Diabetes
|
N/A | |
Terminated |
NCT04031404 -
Glucose and Non-Invasive Brain Stimulation
|
N/A | |
Active, not recruiting |
NCT03577964 -
Development of Pneumonia Due to Alveolar Glucose Levels in Systemic Hyperglycemia
|
||
Active, not recruiting |
NCT03232008 -
Canderel:Effects on Blood Glucose Concentration and Appetite Scores
|
N/A | |
Completed |
NCT04042142 -
Glucagon Resistance in Patients With NAFLD
|
N/A | |
Active, not recruiting |
NCT05607745 -
Dietary Counseling Coupled With FMT in the Treatment of Obesity and NAFLD - the DIFTOB Study
|
N/A | |
Completed |
NCT04004273 -
Diabetes, Exercise and Liver Fat (DELIVER)
|
N/A | |
Completed |
NCT04082923 -
Effect of Meal Texture on Glucose-metabolism and Gut Hormone Response After Bariatric Surgery
|
N/A |